SCHEMBL1495944

SCHEMBL1495944

NC(=O)c1nnc(OC2CCCNC2)c2cc(-c3cccc(F)c3)sc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 18/20 0.63
KCNH2 Q12809 6/20 0.63
CDK2AP1 O14519 1/20 0.47
MELK Q14680 3/20 0.46
PLK4 O00444 1/20 0.46
GAK O14976 1/20 0.46
JAK2 O60674 1/20 0.46
ULK1 O75385 1/20 0.46
RPS6KA4 O75676 1/20 0.46
STK10 O94804 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
ABL1 P00519 1/20 0.46
EGFR P00533 1/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
FES P07332 1/20 0.46
YES1 P07947 1/20 0.46
LYN P07948 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29924035 1.00 CHEK1 (0.63) CHEK1KCNH2CDK2AP1MELKPLK4
SCHEMBL12172208 0.89 CHEK1 (0.48) CHEK1KCNH2CDK2AP1MELKPLK4
SCHEMBL15976164 0.86 CHEK1 (0.69) CHEK1KCNH2CDK2AP1
SCHEMBL18197235 0.86 CHEK1 (0.69) CHEK1KCNH2CDK2AP1
SCHEMBL1496023 0.82 CHEK1 (0.76) CHEK1KCNH2
SCHEMBL1496020 0.82 CHEK1 (0.76) CHEK1KCNH2
SCHEMBL29900088 0.82 CHEK1 (0.76) CHEK1KCNH2
SCHEMBL1496150 0.82 CHEK1 (0.62) CHEK1KCNH2CDK2AP1MELKPLK4
SCHEMBL29924063 0.82 CHEK1 (0.62) CHEK1KCNH2CDK2AP1MELKPLK4
Hydrochloric Acid SCHEMBL30675400 0.82 CHEK1 (0.75) CHEK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2024-01-11 US claimed
EP-4087561-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2022-11-16 EP claimed
CN-115038439-A Combination cancer therapy with CHK inhibitors 上海华禹生物科技有限公司 2022-09-09 CN claimed
WO-2021141974-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR WU FAN (US) 2021-07-15 WO claimed
US-9487539-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD (CN) 2016-11-08 US claimed
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2024-01-11 US disclosed
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2023-02-16 US disclosed
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2023-02-16 US disclosed
EP-4087561-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2022-11-16 EP disclosed
CN-115038439-A Combination cancer therapy with CHK inhibitors 上海华禹生物科技有限公司 2022-09-09 CN disclosed
WO-2021141974-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR WU FAN (US) 2021-07-15 WO disclosed
US-9487539-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD (CN) 2016-11-08 US disclosed
US-8815863-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2014-08-26 US disclosed
US-8815863-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2014-08-26 US disclosed
EP-2477496-B1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION WU ZHANGGUI (US) 2014-04-16 EP disclosed
US-20120232082-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2012-09-13 US disclosed
US-20120232082-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2012-09-13 US disclosed
EP-2477496-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION Wu, Zhanggui (US) 2012-07-25 EP disclosed
WO-2011035077-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION WU ZHANGGUI (US) 2011-03-24 WO disclosed
WO-2011035077-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION WU ZHANGGUI (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR CHEK1, DCK, CHEK2 CHEK1 1/4885KCNH2 4446/4885CDK2AP1 354/4885
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR CHEK1, CHEK2, DCK CHEK1 1/4885KCNH2 4526/4885CDK2AP1 282/4885
US-20120232082-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION CHEK2, CHEK1, BUB1B CHEK1 2/4885KCNH2 4004/4885CDK2AP1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.